Journey Coaching

Research evidence around psilocybin by Centre for Psychedelic Research at Imperial College London has published in the New England Journal of Medicine 2021 that psilocybin has been as effective as anti depressants and greater in results for treating depression with fewer side effects. They suggest to replicate the study on a larger scale in future.

The article is found here and the study here. 

​

In a 2016 gold standard study, 51 cancer patients with life-threatening diagnoses participated. Results showed that more than 80% of participants had significant reduction in anxiety and depression. The study is found here.

​

There is further supporting evidence by Yale scientists that psilocybin assists in creating new neural connections in both mice and pig brains. This was the reason suspected for aiding neuro plasticity with long lasting effects on new decision making abilities and positive mood changes - like reduction in anxiety and depression. Links to the studies are found here.

​

New neural connections are the reason we tend to understand and see old situations from new perspectives induced by the psylocibin.

The study published in the Neuron

Journal showed that there was not only

a significant 10% increase in the

number of neuronal connections

but they were also on average

about 10% larger.

This means that the connections

were stronger due to an increased

number of dendrites - which aid

connections between the neurons.

See the study here with two articles

and their respective studies here.

The article by the American Association

for the Advancement of Science (AAAS) is found here.

​

Between 1 March 2019-27 Sept 2022 the phase 2b clinical trial was conducted at 22 sites in 10 countries across Europe (Czech Republic, Denmark, Germany, Ireland, the Netherlands, Portugal, Spain and the United Kingdom) and North America (Canada and the United States). 233 participants with treatment-resistant depression were allocated at random to receive one of a single 25 mg, 10 mg or 1 mg dose of psilocybin (the control group). Neither the participants nor the researchers were aware which dose the participant had received (double blind experiment- gold standard).

Published in the most prestigious peer-reviewed journal in the world. Positive results showed in a particularly difficult to treat group of patients (treatment resistant depression), and the highest dose of COMP360 psilocybin had the greatest impact on people’s depression. Published in The New English Journal of Medicine found HERE. 

​

In 2023 a double-blind, randomised clinical trial, 52 participants diagnosed with major depressive disorder were allocated to receive either a single, moderate dose (0.215 mg/kg body weight) of psilocybin or a placebo in conjunction with psychological support. The trial took place between April 11th, 2019 and October 12th, 2021 at the psychiatric university hospital in Zürich, Switzerland. These results suggest that a single, moderate dose of psilocybin significantly reduces depressive symptoms compared to a placebo condition for at least two weeks.  HERE

​

Please note:

If you are on any medication discuss this with the facilitator. If you have schizophrenia or a predisposition (schizophrenia runs in the family), or have had any psychotic episodes then a

journey is not recommended.

​

 One should decide 

whether to proceed or not if on blood

pressure medication as a psilocybin journey 

might increase blood pressure.

​

A medical and mental health form will

be filled in beforehand for the

facilitator to check for good fit.